ArticleEClinicalMedicine2026
Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Holter of Movement in Patients with Multiple Sclerosis. Acti-SEP Study: Uncontrolled Environment.
Holter of Movement in Patients with Multiple Sclerosis. Acti-SEP Study: Controlled Environment.
Who cites it
1 citing paper in PubMed.
- Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wearable digital health technologies offer a unique opportunity to assess gait at the stride level in real-world settings. Walking impairment is a major cause of disability in multiple sclerosis (MS), yet current clinical metrics lack sensitivity to early and progressive changes in mobility. Methods: We conducted two studies (NCT04888689/NCT04882891) using a wearable device to develop and validate digital mobility outcome measures based on individual strides in patients with MS. First, we assessed technical performance in a controlled, single-center environment between September 12 and September 18, 2021. We then conducted a 12-month longitudinal study under daily living conditions across six sites between March 2021 and January 2024. The evaluated metrics included stride velocity 95th centile, walking distance 90th centile, and strides per hour. Findings: The controlled and longitudinal studies included 21 and 78 participants, respectively. The device demonstrated high stride detection accuracy (precision: 0·99) and a mean absolute error in stride velocity of 0·019 m/s. In the longitudinal study, stride velocity 95th percentile showed excellent reliability (ICC (2,1) = 0·97, SEM = 0·06) and strong agreement with Expanded Disability Status Scale (Spearman's rho = 0·65, p < 0·001) and Timed 25-Foot Walk (Spearman's rho = -0·71, p < 0·001), sensitivity to 12-month progression in both relapsing-remitting and progressive MS (p = 0·049 and p = 0·006, respectively), outperforming the Expanded Disability Status Scale. Walking distance 90th percentile and strides per hour were reliable and valid but less sensitive to progression. Interpretation: Stride velocity 95th percentile derived from real-world, stride-level data, provides a valid, reliable, and sensitive digital outcome for detecting MS progression. It may serve as an early indicator of progression and support the accelerated evaluation of treatments targeting progression. Funding: This study was funded by F. Hoffmann-La Roche Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.